<DOC>
	<DOC>NCT02247128</DOC>
	<brief_summary>At present, a variety of antithrombotic regimens are prescribed in the early postprocedure period after transcatheter aortic valve implantation (TAVI). Dual antiplatelet therapy (DAPT) using aspirin and a thienopyridine in the initial period after TAVI is the recommended strategy; however, mono antiplatelet therapy using aspirin is suggested not to be inferior. In patients with atrial fibrillation (AF) or another indication for oral anticoagulation (OAC), no recommendations on best treatment regimen currently exist although triple therapy (OAC + DAPT) is best avoided due to increased bleeding risk. We hypothesise that the omission of clopidogrel in the first 3 months after TAVI is safer and not less beneficial than the addition of clopidogrel to aspirin (cohort A) or OAC (cohort B).</brief_summary>
	<brief_title>Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation</brief_title>
	<detailed_description>The trial consists of two cohorts: - Cohort A, patients without an indication for OAC prior to TAVI. - Cohort B, patients with an indication for OAC prior to TAVI (eg. atrial fibrillation, mechanic mitral valve prosthesis).</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Heart Defects, Congenital</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Cohort A 1. Patient has provided written informed consent. Cohort B 1. Need for longterm oral anticoagulation; 2. Patient has provided written informed consent. Cohort A 1. Need for longterm oral anticoagulation; 2. Drugeluting stent implantation within 3 months prior to TAVI procedure; 3. Baremetal stent implantation within 1 month prior to TAVI procedure; 4. Allergy or intolerance to aspirin or clopidogrel. Cohort B 1. Drugeluting stent implantation within 3 months prior to TAVI procedure; 2. Baremetal stent implantation within 1 month prior to TAVI procedure; 3. Use of nonvitamin K oral anticoagulation (NOAC); 4. Allergy or intolerance to OAC or clopidogrel.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Transcatheter Aortic Valve Implantation (TAVI)</keyword>
	<keyword>Transcatheter Aortic Valve Replacement (TAVR)</keyword>
	<keyword>Aortic Valve Disease</keyword>
	<keyword>Aortic Stenosis</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Ischemic stroke</keyword>
	<keyword>Bleeding</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Embolism and Thrombosis</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Prasugrel</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Antithrombotic treatment</keyword>
	<keyword>Oral anticoagulation</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>Genetic Testing</keyword>
	<keyword>Cytochrome P450 2C19 (CYP2C19)</keyword>
	<keyword>Prostaglandin-endoperoxide synthase 2(PTGS2)</keyword>
</DOC>